Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
VOLITIONRX LTD entered into Purchase Agreement with the purchasers listed on the signature pages thereto valued at $1.55 per Share and accompanying Warrant (effective 2026-06-07).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- the purchasers listed on the signature pages thereto
- Value
- $1.55 per Share and accompanying Warrant
- Effective
- 2026-06-07
Exact text from the filing
On June 7, 2026, VolitionRx Limited (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers listed on the signature pages thereto (the “Purchasers”), in connection with the Company’s offer of an aggregate of 2,960,000 shares (the “Shares”) of its common stock, par value $0.001 per share (the “Common Stock”), together with accompanying common stock purchase warrants to purchase 1,480,000 shares of Common Stock (the “Warrants” and, together with the Shares, the “Securities”) to the Purchasers and other investors who purchased Securities pursuant to the prospectus registering such Securities (the “Offering”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
VOLITIONRX LTD entered into Placement Agency Agreement with Maxim Group LLC (effective 2026-06-07).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- Maxim Group LLC
- Effective
- 2026-06-07
Exact text from the filing
The Offering was conducted as a confidentially marketed public offering on a reasonable best efforts basis by Maxim acting as sole placement agent for the Company pursuant to a Placement Agency Agreement, dated June 7, 2026 (the “Placement Agency Agreement”).
View on SEC.gov